Bio-Rad Launches SEQuoia Express Stranded RNA Library Prep Kit at AGBT 2022
Enables Highly Efficient, Optimal RNA-Seq Library Preparation for Comprehensive Transcriptome Profiling
HERCULES, Calif. — June 6, 2022 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the SEQuoia Express Stranded RNA Library Prep Kit. The kit provides biopharmaceutical and research scientists with an easy-to-use solution for constructing robust libraries to support efficient RNA-Seq workflows for comprehensive transcriptome profiling.
The SEQuoia Express Stranded RNA Library Prep Kit offers a cost-effective and automation-friendly solution to the current challenges in library generation. The three-tube kit uses a novel reverse transcriptase alongside a ligation-free adaptor addition chemistry to yield a reproducible, quantitative RNA-Seq library in three hours. The kit enables researchers to construct robust libraries that capture mRNA and long noncoding RNA (>200 bp) transcripts for differential gene expression analysis and novel transcript discovery. Bio-Rad™ provides a complementary and customized bioinformatics solution to streamline the full next-generation sequencing (NGS) workflow, from library preparation to data analysis.
“Current RNA library preparation approaches are time-consuming, complex, and potentially error-prone, with sample loss observed at each stage in processes with multiple steps,” said Simon May, Executive Vice President and President, Life Science Group, Bio-Rad. “Bio-Rad offers scientists an enhanced solution, combining its rapid NGS library preparation with integrated data analysis to overcome these difficulties and enable the widespread adoption of RNA-based sequencing."
Please visit bio-rad.com/SEQuoiaExpress to learn more about Bio-Rad’s SEQuoia Express Stranded RNA Library Prep Kit.
Bio-Rad will be attending the Advances in Genome Biology and Technology (AGBT) General Meeting in Orlando, FL June 6–9, 2022. Join Bio-Rad’s speaker sessions on June 7 and 9 (Parlor Suite 709) to find out more about its novel RNA-Seq workflow or visit its poster presentations on June 8 (Posters #544 and 596).
BIO-RAD is trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,900 employees worldwide. Bio-Rad had revenues of $2.9 billion in 2021. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Bio-Rad Laboratories, Inc.
Kate Smith, Director, Marketing
510-741-5307
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com
To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com. To view our privacy policy, click here.